Scottish Medicines Consortium has approved Nintedanib for Idiopathic Pulmonary Fibrosis patients in Scotland
The Scottish Medicines Consortium (SMC) has today announced that the drug Nintedanib has been approved for Idiopathic Pulmonary Fibrosis patients in Scotland.
Action for Pulmonary Fibrosis contributed to the appraisal process by written submission and by the Chairman, Mike Bray, attending a key meeting in Glasgow as a patient expert in order to give evidence supporting the drug’s approval.
The Scottish Medicines Consortium has accepted OFEV® (Nintedanib) for use in adult patients with IPF with a predicted forced vital capacity (FVC) less than or equal to 80%.
The advice states that OFEV®, compared to placebo, reduces the decline in pulmonary function assessed by FVC in patients with IPF.
The full advice can be found at the link below:
This approval will only benefit IPF patients in Scotland as the decision regarding whether NICE will approve Nintedanib is awaited.